A randomized, phase IIIB, open-label, two-arm, multicenter, comparatiVe study on efficacy and safety of lipegfilgrastim (Lonquex, TEVA) in comparison to pegfilgrastim (Neulasta, Amgen) in elderly patients with aggressive B cell Non-HOdgkin lymphomas at hIgh risk for R-CHOP-21-inDuced neutropenia – AVOID Neutropenia

Trial Profile

A randomized, phase IIIB, open-label, two-arm, multicenter, comparatiVe study on efficacy and safety of lipegfilgrastim (Lonquex, TEVA) in comparison to pegfilgrastim (Neulasta, Amgen) in elderly patients with aggressive B cell Non-HOdgkin lymphomas at hIgh risk for R-CHOP-21-inDuced neutropenia – AVOID Neutropenia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Lipegfilgrastim (Primary) ; Pegfilgrastim
  • Indications Neutropenia; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms AVOID Neutropenia
  • Sponsors Merckle
  • Most Recent Events

    • 30 Aug 2017 Planned End Date changed from 30 Nov 2017 to 16 May 2018.
    • 30 Aug 2017 Planned primary completion date changed from 31 Oct 2017 to 15 Dec 2017.
    • 30 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top